Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.46 |
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334287 | 0.91 | ESR2 (0.54) | ESR2ESR1ALDH5A1ABATMAPT | |
| SCHEMBL1335825 | 0.91 | ESR2 (0.48) | ESR2ESR1ALDH5A1ABATMAPT | |
| SCHEMBL28988665 | 0.90 | ESR2 (0.55) | ESR2ESR1ALDH5A1ABATMAPT | |
| SCHEMBL14575804 | 0.79 | ESR2 (0.37) | ESR2ESR1ALDH5A1ABAT | |
| SCHEMBL8290260 | 0.77 | CYP2A6 (0.41) | HPGDALDH1A1KMT2ATDP1PKM | |
| SCHEMBL4046273 | 0.77 | CYP2A6 (0.36) | RAB9AMEN1NPC1KMT2A | |
| SCHEMBL9939958 | 0.77 | PDE4A (0.31) | — | |
| SCHEMBL695920 | 0.77 | HSD17B10 (0.41) | LMNAKMT2AHSD17B10 | |
| SCHEMBL12345138 | 0.77 | POLB (0.43) | ESR2ESR1MAPTHPGDCYP3A4 | |
| SCHEMBL568885 | 0.76 | MEN1 (0.41) | ALDH1A1MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101171009-A | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3- receptor ligands | BIOPROJET SOC CIV (FR) | 2008-04-30 | — | — | CN | claimed |
| EP-2674428-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2016-04-06 | — | — | EP | disclosed |
| CN-104159892-A | Substituted phenyl azole derivatives | DAIICHI SANKYO CO LTD | 2014-11-19 | — | — | CN | disclosed |
| CN-101171009-B | Use of non-imidazole alkylamines histamine h3- receptor ligands in treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia | BIOPROJET SOC CIV | 2012-11-07 | — | — | CN | disclosed |
| EP-2016065-B1 | 1-(BENZO[D][1,3]DIOXOL-5-YL)-N-(PHENYL)CYCLOPROPANE-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS FOR THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| EP-2000462-A2 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2008-12-10 | — | — | EP | disclosed |
| CN-101171009-A | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3- receptor ligands | BIOPROJET SOC CIV (FR) | 2008-04-30 | — | — | CN | disclosed |
| US-7169928-B2 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SOCIETE CIVILE BIOPROJECT (FR) | 2007-01-30 | — | — | US | disclosed |
| US-7138413-B1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SOCIETE CIVILE BIOPROJET (FR) | 2006-11-21 | — | — | US | disclosed |
| WO-2005051904-A2 | NOVEL PROCESSES FOR THE SYNTHESIS OF CYCLOPROPYL COMPOUNDS | PHARMACIA CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SCHWARTZ JEAN-CHARLES (FR) | 2004-11-04 | — | — | US | disclosed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1428820-A1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2004-06-16 | — | — | EP | disclosed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | HTR1A, HRH4, HTR1D | ESR2 1694/4885ESR1 946/4885ALDH5A1 4220/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | ESR2 1122/4885ESR1 1329/4885ALDH5A1 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.